Oruka Therapeutics, Inc. (NASDAQ:ORKA)
| Market Cap | $6.50B+220.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a-39.7% |
| EPS | n/a+27.2% |
| Shares Out | 67.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,977,006 |
| Open | $95.74 |
| Previous Close | $97.57 |
| Day's Range | $93.42 - $96.80 |
| 52-Week Range | $25.23 - $115.52 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $131.33(+37.07%) |
| Earnings Date | n/a |
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating ORKA in the last 3 months, one vote each. Issuer-paid research is not counted.
$ORKA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ORKA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ORKA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ORKA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ORKA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ORKA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ORKA
| XBIState Street SPDR S&P Biotech ETF | $161.50M |
| VTIVanguard Morningstar Total Stock Market ETF | $145.37M |
| IWMiShares Russell 2000 ETF | $128.90M |
| VBVanguard Morningstar Small-Cap ETF | $64.65M |
| VXFVanguard Extended Market ETF | $62.60M |
| IWOiShares Russell 2000 Growth ETF | $46.40M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ORKA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive Phase 2 psoriasis data and Q3 results balance concerns about valuation and insider selling activity.
Recent Insider Activity
Insider Score Trend Over Time
-32.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 4.54% |
| XBI | State Street SPDR S&P Biotech ETF | 1.72% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 1.62% |
| WDNA | WisdomTree BioRevolution Fund | 1.33% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.13% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 1.11% |
| TDNA | T. Rowe Price Biotech ETF | 1.05% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 1.02% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 0.84% |
| MEDI | Harbor Health Care ETF (MEDI) | 0.77% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.74% |
| CGMM | Capital Group U.S. Small and Mid Cap ETF | 0.54% |
Weight is the stock’s share of each fund’s holdings.
